Taken together, these findings confirm the in vivo therapeutic activity of the ALCAM-blocking parental antibody construct IF8-Fc and the affinity-matured and stability-optimized clone V2D7 in scFv format in a mouse model of asthma. The gene discussed is ALCAM; the disease is asthma.